The Diagnostic and Prognostic Utility of Procalcitonin (ProCT) for Ventilator-associated Pneumonia (VAP)

NCT00498121 | Terminated DMC

• 1 other identifier: BMA-07-001 (mbasi100)
• Study Type: observational
• Target: 50
• Locations: 1 country
• Sites: 1

Brief Summary

Our aim in this study is to investigate the potential role of serum ProCT as an early diagnostic marker and later prognostic indicator for VAP.

Conditions

Ventilator Associated Pneumonia

Keywords

Ventilator associated pneumonia.; Procalcitonin.

Outcome Measures

Primary Outcomes (1)

• Cases with VAP and high ProCT and Cases with Non-VAP and Low ProCT

  Retrospective chart review after results are available

Study Arms (1)

VAP patient

Device: PROCALCITONIN LEVEL

Interventions

PROCALCITONIN LEVEL DEVICE

measuring PROCALCITONIN LEVEL

VAP patient

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients who are intubated or more than 48 hours

You may qualify if:

• In the preceding 24 h, the appearance of a new opacity or opacities on chest X-ray when compared to previous, and two of the following:
• white blood cell count \> 12 or \< 5 x 10\^9 cells/L,
• temperature \> 38°C or \< 35°C, or
• purulent secretions.endotracheal samples must be collected by bronchoscope/bronchoalveolar lavage with quantitative culture or endotracheal aspiration with quantitative culture (when available) or qualitative culture from each patient to be enrolled in the study. This is a routine procedure done in every case of suspected VAP and is considered to be the standard of care.

You may not qualify if:

• Known underlying chronic inflammatory condition of the lung (e.g., sarcoidosis, vasculitis)
• Thyroid cancer patients
• neutropenia (neutrophils \< 0.5 x 10\^9 cells/L
• Concomitant AIDS
• Solid organ transplantation with severe immunosuppression
• New Antibiotic use for more than 18 hrs before blood sample collection
• Severe pancreatitis
• Attending physician does not agree with enrollment into the study.

Sponsors & Collaborators

• McGill University Health Centre/Research Institute of the McGill University Health Centre: lead

Study Sites (1)

McGill University Health Centre

Montreal, Quebec, H3A 1A1, Canada

Location

Related Publications (1)

• Duflo F, Debon R, Monneret G, Bienvenu J, Chassard D, Allaouchiche B. Alveolar and serum procalcitonin: diagnostic and prognostic value in ventilator-associated pneumonia. Anesthesiology. 2002 Jan;96(1):74-9. doi: 10.1097/00000542-200201000-00018.

  PMID: 11753005 BACKGROUND

MeSH Terms

Conditions

Pneumonia, Ventilator-Associated

Condition Hierarchy (Ancestors)

Healthcare-Associated Pneumonia; Cross Infection; Infections; Pneumonia; Respiratory Tract Infections; Lung Diseases; Respiratory Tract Diseases; Iatrogenic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Salman A Qureshi, MD,FRCPSC

  McGill University Health Centre/Research Institute of the McGill University Health Centre

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER

Study Record Dates

• First Submitted: July 6, 2007
• First Posted: July 9, 2007
• Study Start: July 1, 2007
• Study Completion: May 1, 2009
• Last Updated: December 18, 2009

Record last verified: 2009-12

Locations

CA (1)